307 related articles for article (PubMed ID: 23714558)
21. Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".
Jarkowski A; Norris L; Trinh VA
Ann Pharmacother; 2014 Nov; 48(11):1456-68. PubMed ID: 25056920
[TBL] [Abstract][Full Text] [Related]
22. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.
Wolf A; Zia S; Verma R; Pavlick A; Wilson M; Golfinos JG; Silverman JS; Kondziolka D
J Neurooncol; 2016 May; 127(3):607-15. PubMed ID: 26852222
[TBL] [Abstract][Full Text] [Related]
23. Melanoma brain metastases: an unmet challenge in the era of active therapy.
Gorantla V; Kirkwood JM; Tawbi HA
Curr Oncol Rep; 2013 Oct; 15(5):483-91. PubMed ID: 23954973
[TBL] [Abstract][Full Text] [Related]
24. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapy for melanoma: rational combinatorial approaches.
Kwong LN; Davies MA
Oncogene; 2014 Jan; 33(1):1-9. PubMed ID: 23416974
[TBL] [Abstract][Full Text] [Related]
26. Vemurafenib and radiation therapy in melanoma brain metastases.
Narayana A; Mathew M; Tam M; Kannan R; Madden KM; Golfinos JG; Parker EC; Ott PA; Pavlick AC
J Neurooncol; 2013 Jul; 113(3):411-6. PubMed ID: 23579338
[TBL] [Abstract][Full Text] [Related]
27. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
Gibney GT; Zager JS
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
[TBL] [Abstract][Full Text] [Related]
28. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
29. Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R; Vordermark D; Hassel JC; Krex D; Wendl C; Schadendorf D; Sickmann T; Rieken S; Pukrop T; Höller C; Eigentler TK; Meier F
Cancer Treat Rev; 2020 Sep; 89():102083. PubMed ID: 32736188
[TBL] [Abstract][Full Text] [Related]
30. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
31. Sequence-dependent cross-resistance of combined radiotherapy plus BRAF
Shannan B; Matschke J; Chauvistré H; Vogel F; Klein D; Meier F; Westphal D; Bruns J; Rauschenberg R; Utikal J; Forschner A; Berking C; Terheyden P; Dabrowski E; Gutzmer R; Rafei-Shamsabadi D; Meiss F; Heinzerling L; Zimmer L; Livingstone E; Váraljai R; Hoewner A; Horn S; Klode J; Stuschke M; Scheffler B; Marchetto A; Sannino G; Grünewald TGP; Schadendorf D; Jendrossek V; Roesch A
Eur J Cancer; 2019 Mar; 109():137-153. PubMed ID: 30721788
[TBL] [Abstract][Full Text] [Related]
32. Current Treatment of Melanoma Brain Metastasis.
Rishi A; Yu HM
Curr Treat Options Oncol; 2020 Apr; 21(6):45. PubMed ID: 32350685
[TBL] [Abstract][Full Text] [Related]
33. Mutational Status and Clinical Outcomes Following Systemic Therapy with or without Focal Radiation for Resected Melanoma Brain Metastases.
Vasudevan HN; Susko MS; Ma L; Nakamura JL; Raleigh DR; Boreta L; Fogh S; Theodosopoulos PV; McDermott MW; Tsai KK; Sneed PK; Braunstein SE
World Neurosurg; 2023 Feb; 170():e514-e519. PubMed ID: 36400359
[TBL] [Abstract][Full Text] [Related]
34. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM
Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768
[TBL] [Abstract][Full Text] [Related]
35. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
36. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
37. The biology and therapeutic management of melanoma brain metastases.
Abate-Daga D; Ramello MC; Smalley I; Forsyth PA; Smalley KSM
Biochem Pharmacol; 2018 Jul; 153():35-45. PubMed ID: 29278675
[TBL] [Abstract][Full Text] [Related]
38. Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
Drago JZ; Lawrence D; Livingstone E; Zimmer L; Chen T; Giobbie-Hurder A; Amann VC; Mangana J; Siano M; Zippelius A; Dummer R; Goldinger SM; Sullivan RJ
Melanoma Res; 2019 Feb; 29(1):65-69. PubMed ID: 30376465
[TBL] [Abstract][Full Text] [Related]
39. Frequent Use of Local Therapy Underscores Need for Multidisciplinary Care in the Management of Patients With Melanoma Brain Metastases Treated With PD-1 Inhibitors.
Qian JM; Yu JB; Mahajan A; Goldberg SB; Kluger HM; Chiang VLS
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1113-1118. PubMed ID: 31479702
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Melanoma CNS Metastases.
Jang S; Atkins MB
Cancer Treat Res; 2016; 167():263-79. PubMed ID: 26601867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
